Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC18A3 | Q16572 | 2/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.34 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.34 |
| ▸ | MAOA | P21397 | 6/20 | 0.33 |
| ▸ | MAOB | P27338 | 6/20 | 0.33 |
| ▸ | KDM1A | O60341 | 4/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.33 |
| ▸ | CYP2B6 | P20813 | 3/20 | 0.33 |
| ▸ | BRD4 | O60885 | 3/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | HTR1A | P08908 | 1/20 | 0.33 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6586289 | 0.81 | RECQL (0.38) | KDM1ASLC6A2HTR2CSLC6A3 | |
| SCHEMBL22644564 | 0.78 | SLC18A3 (0.31) | SLC18A3SIGMAR1GAAMAPTAKR1C3 | |
| SCHEMBL24350387 | 0.74 | LMNA (0.34) | MAOAMAOBKDM1ACYP2C19CYP2B6 | |
| SCHEMBL778067 | 0.72 | SLC18A3 (0.44) | SLC18A3SIGMAR1GAAMAPTAKR1C3 | |
| SCHEMBL8111510 | 0.69 | AKR1C3 (0.42) | SLC18A3SIGMAR1AKR1C3AKR1C1LMNA | |
| SCHEMBL8783820 | 0.68 | RIPK1 (0.33) | MAOAMAOBKDM1ACYP2C19CYP2B6 | |
| SCHEMBL29031641 | 0.68 | SLC18A3 (0.44) | SLC18A3SIGMAR1GAAMAPTAKR1C3 | |
| SCHEMBL1371597 | 0.67 | SLC18A3 (0.40) | SLC18A3SIGMAR1GAAMAPTAKR1C3 | |
| SCHEMBL2013478 | 0.67 | SLC18A3 (0.48) | SLC18A3SIGMAR1GAAMAPTAKR1C3 | |
| SCHEMBL2766491 | 0.66 | SLC18A3 (0.52) | SLC18A3SIGMAR1GAAMAPTAKR1C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3600302-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | United States Government as Represented by The Department of Veterans Affairs (US) | 2020-02-05 | — | — | EP | disclosed |
| WO-2018183762-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS (US) | 2018-10-04 | — | — | WO | disclosed |
| EP-2807152-A1 | AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS | F.HOFFMANN-LA ROCHE AG (CH) | 2014-12-03 | — | — | EP | disclosed |
| EP-2785711-A1 | 2-(PHENYL OR PYRID-3-YL) AMINOPYRIMIDINE DERIVATIVES AS KINASE LRRK2 MODULATORS FOR THE TREATMENT OF PARKINSON'S DISEASE | F.HOFFMANN-LA ROCHE AG (CH) | 2014-10-08 | — | — | EP | disclosed |
| EP-2785699-A1 | 2-PHENYLAMINOPYRIMIDINE DERIVATIVES AS KINASE LRRK2 MODULATORS FOR THE TREATMENT OF PARKINSON'S DISEASE | F.HOFFMANN-LA ROCHE AG (CH) | 2014-10-08 | — | — | EP | disclosed |
| EP-2785709-A1 | AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS | F.HOFFMANN-LA ROCHE AG (CH) | 2014-10-08 | — | — | EP | disclosed |
| EP-2638031-A1 | PYRAZOLE AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS | F.HOFFMANN-LA ROCHE AG (CH) | 2013-09-18 | — | — | EP | disclosed |
| WO-2013079505-A1 | AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2013-06-06 | — | — | WO | disclosed |
| WO-2013079495-A1 | 2-(PHENYL OR PYRID-3-YL) AMINOPYRIMIDINE DERIVATIVES AS KINASE LRRK2 MODULATORS FOR THE TREATMENT OF PARKINSON'S DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2013-06-06 | — | — | WO | disclosed |
| WO-2013079494-A1 | 2-PHENYLAMINOPYRIMIDINE DERIVATIVES AS KINASE LRRK2 MODULATORS FOR THE TREATMENT OF PARKINSON'S DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2013-06-06 | — | — | WO | disclosed |
| WO-2013079493-A1 | AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2013-06-06 | — | — | WO | disclosed |
| WO-2012062783-A1 | PYRAZOLE AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-05-18 | — | — | WO | disclosed |
| EP-1487436-A4 | COMBINATION THERAPY FOR TREATING, PREVENTING OR MANAGING PROLIFERATIVE DISORDERS AND CANCERS | SIGNAL PHARM INC (US) | 2009-06-03 | — | — | EP | disclosed |
| EP-1539135-A1 | TREATMENT OF DYSKINESIA | Motac Neuroscience Limited (GB) | 2005-06-15 | — | — | EP | disclosed |
| EP-1487436-A1 | COMBINATION THERAPY FOR TREATING, PREVENTING OR MANAGING PROLIFERATIVE DISORDERS AND CANCERS | Signal Pharmaceuticals, Inc. (US) | 2004-12-22 | — | — | EP | disclosed |
| WO-2004026299-A1 | TREATMENT OF DYSKINESIA | MOTAC NEUROSCIENCE LIMITED (GB) | 2004-04-01 | — | — | WO | disclosed |
| EP-1363891-A2 | ANTHRONE DERIVATIVES AND THEIR USE AS JNK INHIBITORS | SIGNAL PHARMACEUTICALS, INC. (US) | 2003-11-26 | — | — | EP | disclosed |
| WO-2003075917-A1 | COMBINATION THERAPY FOR TREATING, PREVENTING OR MANAGING PROLIFERATIVE DISORDERS AND CANCERS | SIGNAL PHARMACEUTICALS, INC. (US) | 2003-09-18 | — | — | WO | disclosed |
| WO-2002066450-A2 | ANTHRONE DERIVATIVES AND THEIR USE AS INK INHIBITORS | SIGNAL PHARMACEUTICALS, INC. (US) | 2002-08-29 | — | — | WO | disclosed |